Thiazolidinediones (TZDs) target peroxisome proliferator–activated receptor-γ (PPAR-γ) and are widely prescribed to treat type 2 diabetes but are associated with substantial weight gain. This side ...
The peroxisome proliferator–activated receptor-γ (PPAR-γ) is a nuclear receptor that is activated by lipids to induce the expression of genes involved in lipid and glucose metabolism, thereby ...
CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant ...
BOSTON -- The investigational agent seladelpar improved markers of disease activity and pruritus in patients with primary biliary cholangitis (PBC) at risk of disease progression, a phase III trial ...
Chronic myeloid leukemia (CML) is a myeloproliferative disease that occurs because of a translocation between chromosomes 9 and 22 in hematopoietic stem cells. The switch results in a fusion of the ...
The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome ...
The growing challenge in cancer therapy lies in overcoming tumor heterogeneity, drug resistance, and associated side effects. Peroxisome proliferator-activated receptors (PPARs) are pivotal regulators ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results